Immediate Impact
19 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
2025 Standout
Works of Estefanía Monturus being referenced
Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy.
2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Estefanía Monturus | 44 | 8 | 25 | 18 | 6 | 51 | |
| M.F. Mosele | 49 | 8 | 36 | 17 | 4 | 52 | |
| Qilong Zhang | 41 | 14 | 11 | 29 | 8 | 50 | |
| Stephen Giilck | 21 | 13 | 13 | 10 | 5 | 34 | |
| Diana Bello Roufai | 30 | 5 | 10 | 16 | 8 | 44 | |
| Anna Pous | 31 | 5 | 8 | 17 | 7 | 53 | |
| Victoria Attaya | 60 | 14 | 20 | 10 | 6 | 66 | |
| Álvaro Montaño | 56 | 13 | 9 | 12 | 7 | 73 | |
| Shahid Ashfaque | 67 | 12 | 16 | 45 | 7 | 76 | |
| Beshara Sheehan | 17 | 8 | 24 | 46 | 5 | 58 | |
| Shu Yazaki | 40 | 15 | 9 | 11 | 8 | 43 |
All Works
Loading papers...